Projected Earnings: cbdMD is expected to report an EPS of -$0.45 for the upcoming quarter, indicating a potential decline from the previous quarter’s EPS of -$0.15.
Revenue Trends: Anticipated revenue for the quarter is around $4.81 million, slightly down from $5.17 million in the previous quarter.
Financial Health: Despite a projected revenue dip, cbdMD ended the fiscal year with a stronger cash position and reduced its net loss by $19.1 million year over year.

cbdMD, Inc. (NYSE American: YCBD) is a well-known company in the CBD industry, offering products under brands like cbdMD and Paw CBD. They have also ventured into the functional mushroom market with ATRx Labs. As a leader in the CBD market, cbdMD competes with other companies in the wellness and health sector, focusing on innovative and quality products.
YCBD is set to release its quarterly earnings on December 20, 2024, with Wall Street estimating an earnings per share (EPS) of -$0.45. This comes after the company reported an EPS of -$0.15 for the previous quarter, indicating a potential decline. Despite this, cbdMD has shown financial improvement, reducing its net loss by $19.1 million year over year.
The projected revenue for the upcoming quarter is approximately $4.81 million. In the previous quarter, cbdMD reported a revenue of $5.17 million, suggesting a slight decrease. The company ended the fiscal year with a stronger cash position, which may help offset the anticipated revenue dip.
cbdMD’s gross profit for the last quarter was around $3.40 million, with a cost of revenue at $1.77 million. This indicates a healthy margin, although the operating income was a negative $382,028, showing an operating loss. The EBITDA was $1.06 million, reflecting the company’s efforts to improve its financial health.